Publications by authors named "Maria Trypaki"

Claim this Profile
L
LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer.
Eleni D Lagoudaki, Anastasios V Koutsopoulos, Maria Sfakianaki, Chara Papadaki, Georgios C Manikis, Maria Trypaki

Cancers (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Value of Mutations in Colorectal Cancer Patients.
Asimina Koulouridi, Michaela Karagianni, Ippokratis Messaritakis, Maria Sfakianaki, Alexandra Voutsina, Maria Trypaki

Cancers (Basel)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies.
Andreas Koulouris, Christos Tsagkaris, Ippokratis Messaritakis, Nikolaos Gouvas, Maria Sfakianaki, Maria Trypaki

Cancers (Basel)· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer.
Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, Stavroula Manolakou

Cancers (Basel)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study.
Chara Papadaki, Stavroula Manolakou, Eleni Lagoudaki, Spyros Pontikakis, Despo Ierodiakonou, Maria Trypaki

Cancers (Basel)· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer.
Georgios Ioannidis, Chara Papadaki, Eleni Lagoudaki, Maria Tzardi, Maria Trypaki

Anticancer Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer.
Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, Sardar Alam

Cancer Res Treat· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.
Galatea Kallergi, Eleni-Kyriaki Vetsika, Despoina Aggouraki, Eleni Lagoudaki, Anastasios Koutsopoulos, Maria Trypaki

Ther Adv Med Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer.
Alexios Matikas, Alexandra Voutsina, Eleni Lagoudaki, Dora Hatzidaki, Maria Trypaki

Transl Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of circulating free DNA in colorectal cancer.
Alexios Matikas, Alexandra Voutsina, Maria Trypaki, Vassilis Georgoulias

World J Gastrointest Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide.
Niki Karachaliou, Chara Papadaki, Eleni Lagoudaki, Maria Trypaki, Maria Sfakianaki

PLoS One· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Chara Papadaki, Maria Sfakianaki, Georgios Ioannidis, Eleni Lagoudaki, Maria Trypaki

J Thorac Oncol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.
Zacharenia Saridaki, Maria Tzardi, Chara Papadaki, Maria Sfakianaki, Fraga Pega, Maria Trypaki

PLoS One· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.
Aristea Kalikaki, Anastasios Koutsopoulos, Dora Hatzidaki, Maria Trypaki, Emmanouel Kontopodis

Lung Cancer· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.
Chara Papadaki, Dimitris Mavroudis, Maria Trypaki, Anastasios Koutsopoulos, Efstathios Stathopoulos

Clin Cancer Res· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Ioannis Boukovinas, Chara Papadaki, Pedro Mendez, Miquel Taron, Dimitris Mavroudis, Maria Trypaki

PLoS One· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis